Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Total Current Liabilities: 2016-2024

Historic Total Current Liabilities for Collegium Pharmaceutical (COLL) over the last 9 years, with Dec 2024 value amounting to $509.5 million.

  • Collegium Pharmaceutical's Total Current Liabilities fell 1.41% to $452.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $452.9 million, marking a year-over-year decrease of 1.41%. This contributed to the annual value of $509.5 million for FY2024, which is 11.27% up from last year.
  • Per Collegium Pharmaceutical's latest filing, its Total Current Liabilities stood at $509.5 million for FY2024, which was up 11.27% from $457.9 million recorded in FY2023.
  • In the past 5 years, Collegium Pharmaceutical's Total Current Liabilities registered a high of $509.5 million during FY2024, and its lowest value of $239.5 million during FY2020.
  • Its 3-year average for Total Current Liabilities is $467.1 million, with a median of $457.9 million in 2023.
  • Data for Collegium Pharmaceutical's Total Current Liabilities shows a peak YoY spiked of 55.14% (in 2022) over the last 5 years.
  • Collegium Pharmaceutical's Total Current Liabilities (Yearly) stood at $239.5 million in 2020, then increased by 16.75% to $279.6 million in 2021, then surged by 55.14% to $433.7 million in 2022, then increased by 5.58% to $457.9 million in 2023, then increased by 11.27% to $509.5 million in 2024.